Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
San Diego, CA
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
San Diego, CA
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Palm Harbor, FL
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Flint, MI
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Flint, MI
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Flint, MI
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Flint, MI
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Morehead City, NC
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Morehead City, NC
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Medford, OR
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Medford, OR
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Greenville, SC
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Spartanburg, SC
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Spartanburg, SC
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Dallas, TX
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Dallas, TX
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Dallas, TX
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Federal Way, WA
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Federal Way, WA
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
Clinical Research Facility
mi
from
Tacoma, WA
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated:  2/12/2016
mi
from
Yaroslavl,
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Status: Enrolling
Updated: 2/12/2016
mi
from
Yaroslavl,
Click here to add this to my saved trials
Inhaled Bicarbonate Therapy in Cystic Fibrosis
Inhaled Bicarbonate Therapy in Cystic Fibrosis
Status: Enrolling
Updated:  2/12/2016
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Inhaled Bicarbonate Therapy in Cystic Fibrosis
Inhaled Bicarbonate Therapy in Cystic Fibrosis
Status: Enrolling
Updated: 2/12/2016
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Buspirone as a Potential Treatment for Recurrent Central Apnea
Buspirone as a Potential Treatment for Recurrent Central Apneas
Status: Enrolling
Updated:  2/16/2016
VA Medical Center, Cleveland
mi
from
Cleveland, OH
Buspirone as a Potential Treatment for Recurrent Central Apnea
Buspirone as a Potential Treatment for Recurrent Central Apneas
Status: Enrolling
Updated: 2/16/2016
VA Medical Center, Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Gulf Shores, AL
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Gulf Shores, AL
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Mobile, AL
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Tucson, AZ
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Riverside, CA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Riverside, CA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Fort Collins, CO
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Wheat Ridge, CO
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Glastonbury, CT
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Glastonbury, CT
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Stamford, CT
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Stamford, CT
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Waterbury, CT
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Waterbury, CT
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigator Site
mi
from
Clearwater, FL
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigator Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Hialeah, FL
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Hialeah, FL
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Miami, FL
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Miami, FL
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Miami, FL
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Oakland Park, FL
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Oakland Park, FL
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Pensacola, FL
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Pensacola, FL
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigator Site
mi
from
Couer D'Alene, ID
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigator Site
mi
from
Couer D'Alene, ID
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Newburgh, IN
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Newburgh, IN
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigator Site
mi
from
Topeka, KA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigator Site
mi
from
Topeka, KA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Florence, KY
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Florence, KY
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Madisonville, KY
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Madisonville, KY
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
New Orleans, LA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Opelousas, LA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Opelousas, LA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Biddeford, ME
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Biddeford, ME
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Worchester, MA
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Worchester, MA
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Edina, MN
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Edina, MN
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Fridley, MN
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Fridley, MN
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigator Site
mi
from
Minneapolis, MN
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigator Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigator Site
mi
from
Minneapolis, MN
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigator Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Fremont, NE
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Fremont, NE
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Omaha, NE
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated:  2/17/2016
Novartis Investigative Site
mi
from
Henderson, NV
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation
Status: Enrolling
Updated: 2/17/2016
Novartis Investigative Site
mi
from
Henderson, NV
Click here to add this to my saved trials